Development asset linked to Peking University Biologics in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
pharma · Adenocarcinoma of Lung · Primary Sjögren's Syndrome
Peking University Biologics
Peking University People's Hospital
Peking University Biologics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
2018 Founded
8 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 8
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Peking University Biologics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Peking University Biologics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Janus Kinase (JAK).
- Target
- Janus Kinase (JAK)
- Mechanism
- Janus Kinase (JAK) inhibitor